Clinical Trial Update: 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating second-line liposomal irinotecan (nal-IRI) after gemcitabine/nab-paclitaxel in locally advanced or metastatic pancreatic cancer, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 3 | Status: COMPLETED